N Engl J Med 2018 Apr 15
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Related Questions
Patients with T3aN1a( stage IIIA per AJCC7) were excluded from nivolumab adjuvant trial. Would you consider nivolumab in these patients?
New answer by Medical Oncologist at Sediman Cancer Center/University Hospitals of Cleveland Case Medical Center (October 11, 2018)
This is a very timely and excellent question. There have been recently three landmark adjuvant studies, and two recent FDA approvals that have changed our approach for patient...